Description
Felvizumab [HuRSV19VHFNS/VK, RSHZ19, RSV monoclonal antibody, SB 209763] is a humanised monoclonal antibody (IgG1) prepared by the humanization of an F protein-specific murine MAb, RSV19. In in vitro studies, palivizumab, another humanized Mab specific for the F protein of RSV, was 4 to 5-fold more potent than felvizumab in neutralising RSV (Scott, 1999). RSHZ19 (Felvizumab) RSV This antibody was
Catalog No.
DVV02804
Host species
Humanized
Species reactivity
HRSV-A
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Concentration
1 mg/ml
Purity
>95% by SDS-PAGE.
Clonality
Monoclonal
Isotype
IgG1, kappa
Applications
Research Grade Biosimilar
Target
F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1
Purification
Protein A or G purified from cell culture supernatant.
Endotoxin level
Please contact with the lab for this information.
Expression system
XtenCHO
Accession
P03420
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Alternative Names
SB 209763, HuRSV19VHFNS/VK, RSHZ19, RSV monoclonal antibody, SB 209763, RSV19, CAS: 167747-20-8, Human Respiratory Syncytial Virus (HRSV)
Note
For research use only. Not suitable for clinical or therapeutic use.
关键字: Felvizumab;DVV02804;Peptide 27;
武汉佰乐博生物(Biolab Reagents )作为普健生物旗下控股子品牌,专注于引进、整合全球业内高品质蛋白、抗体产品。作为法国ProteoGenix、Antibodysystem品牌亚洲区独家运营代理商。提供近2万种以蛋白、抗体为核心的生命科学试剂,旨在为生命科学科研工作者提供专业、全面、可靠的试剂产品。